Last reviewed · How we verify
Protease Inhibitor/ritonavir
Protease Inhibitor/ritonavir is a Protease inhibitor combination Small molecule drug developed by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. It is currently in Phase 3 development for HIV-1 infection.
This combination inhibits HIV protease while ritonavir acts as a pharmacokinetic booster to increase protease inhibitor levels in the bloodstream.
This combination inhibits HIV protease while ritonavir acts as a pharmacokinetic booster to increase protease inhibitor levels in the bloodstream. Used for HIV-1 infection.
At a glance
| Generic name | Protease Inhibitor/ritonavir |
|---|---|
| Sponsor | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
| Drug class | Protease inhibitor combination |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Protease inhibitors block the HIV protease enzyme, preventing the cleavage of viral polyproteins necessary for the production of infectious viral particles. Ritonavir is a potent cytochrome P450 inhibitor that dramatically increases the plasma concentration and half-life of the co-administered protease inhibitor, allowing for lower doses and improved dosing schedules. Together, they suppress HIV replication and reduce viral load in infected individuals.
Approved indications
- HIV-1 infection
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Lipid abnormalities (elevated cholesterol and triglycerides)
- Hepatotoxicity
- Hyperglycemia
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
- Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 (PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir) (PHASE3)
- Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Protease Inhibitor/ritonavir CI brief — competitive landscape report
- Protease Inhibitor/ritonavir updates RSS · CI watch RSS
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia portfolio CI
Frequently asked questions about Protease Inhibitor/ritonavir
What is Protease Inhibitor/ritonavir?
How does Protease Inhibitor/ritonavir work?
What is Protease Inhibitor/ritonavir used for?
Who makes Protease Inhibitor/ritonavir?
What drug class is Protease Inhibitor/ritonavir in?
What development phase is Protease Inhibitor/ritonavir in?
What are the side effects of Protease Inhibitor/ritonavir?
What does Protease Inhibitor/ritonavir target?
Related
- Drug class: All Protease inhibitor combination drugs
- Target: All drugs targeting HIV protease
- Manufacturer: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection
- Compare: Protease Inhibitor/ritonavir vs similar drugs
- Pricing: Protease Inhibitor/ritonavir cost, discount & access